Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Average Rating of “Moderate Buy” from Analysts

Kalaris Therapeutics Inc. (NASDAQ:KLRS) has been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $14.00.

Several research firms have commented on KLRS. Citigroup restated an “outperform” rating on shares of Kalaris Therapeutics in a research note on Thursday, December 18th. Citizens Jmp assumed coverage on shares of Kalaris Therapeutics in a research report on Monday, November 3rd. They issued a “market outperform” rating and a $20.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kalaris Therapeutics in a research report on Monday, December 29th. Wall Street Zen lowered shares of Kalaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Finally, Chardan Capital started coverage on shares of Kalaris Therapeutics in a research report on Tuesday, December 23rd. They set a “buy” rating and a $19.00 price target on the stock.

Kalaris Therapeutics Trading Up 10.7%

KLRS stock opened at $10.02 on Wednesday. The stock has a 50-day moving average price of $8.82 and a two-hundred day moving average price of $6.05. Kalaris Therapeutics has a 1 year low of $2.14 and a 1 year high of $12.90. The stock has a market cap of $187.37 million, a PE ratio of -2.66 and a beta of -0.09.

Kalaris Therapeutics (NASDAQ:KLRS) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.66) by $0.02.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Nano Cap New Millennium Growth Fund L P acquired a new position in shares of Kalaris Therapeutics during the 4th quarter worth approximately $34,000. Johnson Financial Group Inc. acquired a new stake in shares of Kalaris Therapeutics in the 3rd quarter valued at approximately $58,000. XTX Topco Ltd bought a new position in shares of Kalaris Therapeutics in the second quarter valued at $65,000. Bridgeway Capital Management LLC acquired a new position in Kalaris Therapeutics during the third quarter worth $130,000. Finally, Simplify Asset Management Inc. bought a new stake in Kalaris Therapeutics during the fourth quarter worth $169,000. 66.05% of the stock is owned by institutional investors and hedge funds.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.